Telomir filed an annual report on Form 10-K for the year ended Dec. 31, 2025. The company reported no revenue and a net loss of USD 10.41 million, a 37.01% narrower loss year over year. General and administrative expense was USD 8.1 million, down 15.91%, reflecting lower stock-based compensation and reduced IPO-related accounting and legal expenses. Research and development expense was USD 2.44 million. Telomir reported cash of USD 7.29 million and said it expects cash and cash equivalents to fund operations, development plans and capital expenditures through the first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-010625), on March 17, 2026, and is solely responsible for the information contained therein.